Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

BACKGROUND: Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, in patients with intermediate-2 (int-2) or h...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstovsek, Srdan, Gotlib, Jason, Mesa, Ruben A., Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Cervantes, Francisco, Harrison, Claire N., Paquette, Ronald, Sun, William, Naim, Ahmad, Langmuir, Peter, Dong, Tuochuan, Gopalakrishna, Prashanth, Gupta, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622445/
https://www.ncbi.nlm.nih.gov/pubmed/28962635
http://dx.doi.org/10.1186/s13045-017-0527-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622445/
https://www.ncbi.nlm.nih.gov/pubmed/28962635
http://dx.doi.org/10.1186/s13045-017-0527-7

Ejemplares similares